One important caveat: IGF-1 LR3 retains its ability to bind the insulin receptor (IR), forming hybrid IGF1R/IR complexes
Thats why Im pushing for legislation that would require comprehensive coverage for obesity treatments statewide, making these treatments more readily available for all New Yorkers
Owing to the lack of robust clinical data, clinicians and healthcare systems may not be equipped to identify or manage adverse effects associated with these molecules
Dont settle for one-size-fits-all programs when you can access personalized, science-backed weight management that transforms lives
Legitimate peptide therapies [like a GLP-1], intended for human use, require medical oversight, and must be dispensed through licensed pharmacies
That's the next decade of wellness M&A